Format

Send to

Choose Destination
Bioorg Med Chem Lett. 1998 Oct 20;8(20):2891-6.

Quinazolines: combined type 3 and 4 phosphodiesterase inhibitors.

Author information

1
Research, Novartis Pharma AG, Basle, Switzerland. brigitte.charpiot@pharma.novartis.com

Abstract

A series of quinazolines has been prepared and evaluated for its ability to inhibit cyclic AMP phosphodiesterase type 3, type 4A, 4B and 4D. The most potent inhibitors showed IC50 values in the nanomolar range for type 3 and type 4 isoforms and bind with high affinity to the [3H]rolipram binding site. These quinazolines represent a new family of potent mixed PDE 3/4 inhibitors and are expected to have a therapeutic potential.

PMID:
9873643
DOI:
10.1016/s0960-894x(98)00508-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center